Alnylam Pharmaceuticals | Beneficio Operativo



Operating Profit Cambio Fecha
Acadia Pharmaceuticals USD 153.5M 121.86M 2024-12
Agios Pharmaceuticals USD -125037000 1.11B 2024-12
Alnylam Pharmaceuticals USD -105159000 28.25M 2024-12
Amgen USD 2.31B 182M 2024-12
Arrowhead Research USD -161412000 791K 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Incyte USD 301.51M 155.43M 2024-12
Ionis Pharmaceuticals USD -110823000 37.83M 2024-12
Moderna USD -1246000000 1.18B 2024-12
Neurocrine Biosciences USD 142M 41.8M 2024-12
Novartis USD 3.4B 193M 2024-12
PTC Therapeutics USD -62489000 7.98M 2024-12
Regeneron Pharmaceuticals USD 990.2M 189.3M 2024-12
Sanofi EUR 3.64B 1.35B 2024-09
Sarepta Therapeutics USD 161.68M 139.48M 2024-12
Takeda JPY 66.94B 117.3B 2024-12
Tectonic Therapeutic USD -19637000 8.22M 2024-09
Ultragenyx Pharmaceutical USD -122278000 9.71M 2024-12
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12
Xencor USD 4.05M 66.33M 2024-12



Alnylam Pharmaceuticals Beneficio Operativo - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.